Moberg Derma Raises SEK 27,7 Million to Fund Clinical Phase III trial for a Novel Treatment of Nail Fungus (Onychomycosis)

Stockholm, Sweden June 27th, 2007

The Swedish pharmaceutical company Moberg Derma AB, today announced that it has successfully completed the financing of SEK 27,7 million. The Baltic Sea Foundation (Östersjöstiftelsen) was the lead investor and was joined by other institutional and private investors, as well as members of management.

“We are very satisfied with the interest and support from investors. The newly raised funds allow us to start a Phase III trial in September for K101 – a novel topical treatment for onychomycosis (nail fungus). It also helps us to meet our goal of having two products in late-stage clinical development by the end of this year” says Peter Wolpert, CEO of Moberg Derma.


Contact:
Peter Wolpert, CEO
Telephone: +46 (70) 735 7135
Email: peter.wolpert@mobergderma.se
For more information, please visit our website www.mobergderma.se